Andre Luis Branco de Barros

Dr. Andre Luis Branco de Barros

UFMG - Federal University of Minas Gerais
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2013 in ACS Nano
Verified
Journal Article
Open access
AZAjlan Al Zaki
Ajlan Al Zaki
DJDaniel Joh
Daniel Joh
ZCZhiliang Cheng
Zhiliang Cheng
ABAndre Luis Branco de Barros
Andre Luis Branco de Barros
GKGary Kao
Gary Kao
ATAndrew Tsourkas
Andrew Tsourkas
Gold nanoparticles (AuNPs) have generated interest as both imaging and therapeutic agents. AuNPs are attractive for imaging applications since they are nontoxic and provide nearly three times greater X-ray attenuation per unit weight than iodine. As therapeutic agents, AuNPs can sensitize tumor cells to ionizing radiation. To create a nanoplatform that could simultaneously exhibit long circulation times, achieve appreciable tumor accumulation, generate computed tomography (CT) image contrast, and serve as a radiosensitizer, gold-loaded polymeric micelles (GPMs) were prepared. Specifically, 1.9 nm AuNPs were encapsulated within the hydrophobic core of micelles formed with the amphiphilic diblock copolymer poly(ethylene glycol)-b-poly(ε-capralactone). GPMs were produced with low polydispersity and mean hydrodynamic diameters ranging from 25 to 150 nm. Following intravenous injection, GPMs provided blood pool contrast for up to 24 h and improved the delineation of tumor margins via CT. Thus, GPM-enhanced CT imaging was used to guide radiation therapy delivered via a small animal radiation research platform. In combination with the radiosensitizing capabilities of gold, tumor-bearing mice exhibited a 1.7-fold improvement in the median survival time, compared with mice receiving radiation alone. It is envisioned that translation of these capabilities to human cancer patients could guide and enhance the efficacy of radiation therapy.

1 January 2012 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
ABAndre Luis Branco de Barros
Andre Luis Branco de Barros
ATAndrew Tsourkas
Andrew Tsourkas
Babak SabouryBabak Saboury
Babak Saboury
VCValbert N Cardoso
Valbert N Cardoso
Abass AlaviAbass Alavi
Abass Alavi
Nanomedicine is emerging as a promising approach for diagnostic applications. Nanoparticles are structures in the nanometer size range, which can present different shapes, compositions, charges, surface modifications, in vitro and in vivo stabilities, and in vivo performances. Nanoparticles can be made of materials of diverse chemical nature, the most common being metals, metal oxides, silicates, polymers, carbon, lipids, and biomolecules. Nanoparticles exist in various morphologies, such as spheres, cylinders, platelets, and tubes. Radiolabeled nanoparticles represent a new class of agent with great potential for clinical applications. This is partly due to their long blood circulation time and plasma stability. In addition, because of the high sensitivity of imaging with radiolabeled compounds, their use has promise of achieving accurate and early diagnosis. This review article focuses on the application of radiolabeled nanoparticles in detecting diseases such as cancer and cardiovascular diseases and also presents an overview about the formulation, stability, and biological properties of the nanoparticles used for diagnostic purposes.

1 September 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JDJaqueline Aparecida Duarte
Jaqueline Aparecida Duarte
ABAndre Luis Branco de Barros
Andre Luis Branco de Barros
ELElaine Amaral Leite
Elaine Amaral Leite
Statins, typically used to reduce lipid levels, have been rediscovered for exhibiting anticancer activities. Among them, especially simvastatin may influence the proliferation, migration, and survival of cancer cells. The concept of using statins to treat cancer has been adopted since the 1990s In vitro and in vivo experiments and cohort studies using statins have been carried out to demonstrate their antitumor effects (such as proliferation and migration impairment) by influencing inflammatory and oxidative stress-related tumorigenesis. Nevertheless, the biological mechanisms for these actions are not fully elucidated. In this review, we present an overview of the most important studies conducted from 2015 to date on the use of simvastatin in cancer therapy. This review brings the most recent perspectives and targets in epidemiological, in vitro, and in vivo studies, regarding the use of simvastatin alone or in combination with other drugs for the treatment of various types of cancer.

1 May 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ZLZixian Li
Zixian Li
ABAndre Luis Branco de Barros
Andre Luis Branco de Barros
DSDaniel Soares
Daniel Soares
SMSara Nicole Moss
Sara Nicole Moss
LALaleh Alisaraie
Laleh Alisaraie

1 October 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JSJuliana de Oliveira Silva
Juliana de Oliveira Silva
RFRenata Salgado Fernandes
Renata Salgado Fernandes
COCaroline Mari Ramos Oda
Caroline Mari Ramos Oda
TFTiago Hilário Ferreira
Tiago Hilário Ferreira
ABAna Flávia Machado Botelho
Ana Flávia Machado Botelho
ABAndre Luis Branco de Barros
Andre Luis Branco de Barros
Long circulating pH-sensitive liposomes have been shown to effectively deliver doxorubicin (DOX) to tumors and reduce its toxic effects. Folic acid receptors are upregulated in a wide variety of solid, epithelial tumors, including breast cancer. In order to improve liposomal endocytosis and antitumor activity, folic acid has been added to nanoparticles surfaces to exploit overexpression of folate receptors in tumor cells. The purpose of this study was to evaluate the antitumor activity in vitro and in vivo of long circulating pH-sensitive folate-coated DOX-loaded liposomes (SpHL-DOX-Fol) in a 4T1 breast cancer model system in vitro and in vivo. Biodistribution studies were performed and in vivo electrocardiographic parameters were evaluated. A higher tumor uptake for radiolabeled SpHL-Fol (99mTc-SpHL-Fol) 4 h after intravenous administration was observed in comparision with non-folate-coated liposomes (99mTc-SpHL). Antitumor activity showed that SpHL-DOX-Fol treatment led to a 68% growth arrest and drastically reduce pulmonary metastasis foci. Additionally, eletrocardiographic parameters analysis revealed no dispersion in the QT and QTc interval was observed in liposomal treated mice. In summary, this novel multifunctional nanoplatform deomonstrated higher tumor uptake and antitumor activity. SpHL-DOX-Fol represents a drug delivery platform to improve DOX tumor delivery and reduce dose-limiting toxicity.

5 September 2018 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
SNShirleide Santos Nunes
Shirleide Santos Nunes
RFRenata Salgado Fernandes
Renata Salgado Fernandes
CCCarolina Henriques Cavalcante
Carolina Henriques Cavalcante
ICIsabela da Costa César
Isabela da Costa César
ELElaine Amaral Leite
Elaine Amaral Leite
ABAndre Luis Branco de Barros
Andre Luis Branco de Barros